The Carter Center's assistance to river blindness control programs: establishing treatment objectives and goals for monitoring ivermectin delivery systems on two continents.
Periodic mass treatment with ivermectin in endemic communities prevents eye and dermal disease due to onchocerciasis. As part of an international global partnership to control onchocerciasis, The Carter Center's Global 2000 River Blindness Program (GRBP) assists the ministries of health in ten countries to distribute ivermectin (Mectizan, donated by Merck & Co.). The GRBP priorities are to maximize ivermectin treatment coverage and related health education and training efforts, and to monitor progress through regular reporting of ivermectin treatments measured against annual treatment objectives and ultimate treatment goals (e.g., full coverage, which is defined as reaching all persons residing in at risk villages who are eligible for treatment). Since the GRBP began in 1996, more than 21.2 million ivermectin treatment encounters have been reported by assisted programs. In 1999, more than 6.6 million eligible persons at risk for onchocerciasis received treatment, which represented 96% of the 1999 annual treatment objective of 6.9 million, and 78% of the ultimate treatment goal in assisted areas.
Richards
F O
FO
Global 2000 River Blindness Program/The Carter Center, Atlanta Georgia 30307, USA.
Miri
E S
ES
Katabarwa
M
M
Eyamba
A
A
Sauerbrey
M
M
Zea-Flores
G
G
Korve
K
K
Mathai
W
W
Homeida
M A
MA
Mueller
I
I
Hilyer
E
E
Hopkins
D R
DR
D000349:Africa; D005369:Filaricides / Q000600:supply & distribution / Q000627:therapeutic use*; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use*; D015827:Onchocerciasis, Ocular / Q000188:drug therapy* / Q000517:prevention & control*; D015397:Program Evaluation / Q000706:statistics & numerical data; D013020:South America
D005369:Filaricides; D007559:Ivermectin